Document Detail

The effect of staggered administration of zinc sulfate on the pharmacokinetics of oral cephalexin.
MedLine Citation:
PMID:  22023069     Owner:  NLM     Status:  MEDLINE    
AIMS: To investigate the effect of zinc sulfate on pharmacokinetics of cephalexin when administered concurrently or at strategically spaced dosing times designed to avoid the potential interaction in healthy volunteers.
METHODS: In this study, all subjects (n= 12) were randomized to receive the following four treatments, separated by a wash-out period of 7 days: cephalexin 500mg alone, concomitantly with zinc 250mg, 3h after zinc 250mg or 3h before zinc 250mg.
RESULTS: All subjects completed the study safely. Zinc supplements administered concurrently with cephalexin significantly decreased the peak serum concentration (C(max) ), area under the plasma concentration-time curve from zero to infinity (AUC(0-∞) ) and the time for which the plasma concentration of the drug remained above the minimal inhibitory concentration of the pathogenic organism (T > MIC) of cephalexin [mean percentage decrease (95% confidence intervals) of 31.05% (22.09-40.01%), 27.40% (18.33-36.47%) and 22.33% (12.51-32.16%), respectively; P < 0.05] compared with administration of cephalexin alone. Also, administration of zinc 3h before cephalexin decreased the C(max) , AUC(0-∞) and T > MIC of the drug compared with administration of cephalexin alone [mean percentage decrease (95% confidence intervals) of 11.48% (3.40-19.55%), 18.12% (9.63-26.60%) and 23.75% (14.30-33.20%), respectively; P < 0.05]. In contrast, the pharmacokinetics of cephalexin was not notably altered by administration of zinc 3h after cephalexin dosing (P > 0.05).
CONCLUSIONS: The significant interaction between zinc and cephalexin might affect the clinical outcome of cephalexin therapy. The dosing recommendation is that zinc sulfate can be safely administered 3h after a cephalexin dose.
Yi Ding; Yan-Yan Jia; Fan Li; Wen-Xing Liu; Cheng-Tao Lu; Yan-Rong Zhu; Jing Yang; Li-Kun Ding; Lin Yang; Ai-Dong Wen
Related Documents :
2338419 - Pharmacokinetics of imipenem/cilastatin in neutropenic patients with haematological mal...
3758149 - Pharmacokinetics of fluocortolone in man.
7106159 - Pharmacokinetics of tris (hydroxymethyl-)aminomethane in healthy subjects and in patien...
8665999 - Single-dose pharmacokinetics of nefazodone in healthy young and elderly subjects and in...
7463349 - Pharmacological studies on 5-methoxymethyl-2'-deoxyuridine: a new antiviral agent.
1760859 - Clinical pharmacokinetics of mitoxantrone in hyperthermic, isolated perfusion of the leg.
18640499 - Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus co...
15840039 - An extremely high dose of losartan affords superior renoprotection in the remnant model.
20606379 - Effects of various fragrant ingredients on desmopressin-induced fluid retention in mice.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  British journal of clinical pharmacology     Volume:  73     ISSN:  1365-2125     ISO Abbreviation:  Br J Clin Pharmacol     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-02-14     Completed Date:  2012-06-12     Revised Date:  2013-06-27    
Medline Journal Info:
Nlm Unique ID:  7503323     Medline TA:  Br J Clin Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  422-7     Citation Subset:  IM    
Copyright Information:
© 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.
Department of Pharmacy, Xijing Hospital of the Fourth Military Medical University, Xi'an, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Anti-Bacterial Agents / administration & dosage,  pharmacokinetics*
Biological Availability
Cephalexin / administration & dosage,  pharmacokinetics*
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Interactions
Zinc Sulfate / administration & dosage,  pharmacology*
Reg. No./Substance:
0/Anti-Bacterial Agents; 15686-71-2/Cephalexin; 7733-02-0/Zinc Sulfate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Resource utilization before and during infliximab therapy in patients with inflammatory bowel diseas...
Next Document:  Biosynthesis of UDP-glucuronic acid and UDP-galacturonic acid in Bacillus cereus subsp. cytotoxis NV...